ACE inhibitors and severe COVID-19: Protective in older patients?
May 22, 2020
A randomized trial is planned after a study showed that fewer older hypertensive patients taking ACE inhibitors were hospitalized with COVID-19.
New angiotensin studies in COVID-19 give more reassurance
May 6, 2020
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
Diastolic dysfunction is a common risk factor for cognitive decline
May 5, 2020
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic changes, among others.
Remdesivir now ‘standard of care’ for COVID-19, Fauci says
April 30, 2020
The interim results show that time to recovery was 31% faster for patients who received remdesivir than for those who received placebo.
Angiotensin drugs and COVID-19: More reassuring data
April 24, 2020
Data from one Wuhan hospital show no difference in COVID-19 severity or mortality in patients with hypertension taking ACE inhibitors or ARBs. Other reassuring studies are also emerging.
Sodium nitrite disappoints in cardiac arrest
April 16, 2020
The drug did not significantly improve patients’ chances of being admitted to or discharged from the hospital alive in a new study.
Larger absolute rivaroxaban benefit in diabetes: COMPASS
March 29, 2020
The new vascular low dose of rivaroxaban has had a slow start, but these results may stimulate use in patients with diabetes and stable disease.
Dramatic rise in hypertension-related deaths in the United States
March 20, 2020
The ‘alarming’ increase in hypertension-related deaths between 2007 and 2017, was particularly prominent in the rural South.